SAM #75N98026Q01076

Sole Source Metabolomic Analysis Services for PB Effects in ME/CFS Patients (Metabolon, Inc.)

This notice details NIH NHLBI's intent to award a non-competitive contract for metabolomic analysis services related to Phenylbutyrate (PB) effects in ME/CFS patients. - Agency: National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) - Opportunity: Non-competitive service contract for untargeted metabolomic profiling - Vendor: Metabolon, Inc. (sole source, proprietary platform required) - Scope: - Analyze plasma samples from 30 ME/CFS patients and 15 healthy volunteers - Pre- and post-treatment with Phenylbutyrate - Use Metabolon's proprietary metabolomics platform for analytical continuity - Provide bioinformatic analysis to identify metabolic changes and therapeutic effects - NAICS Code: 621511 (Medical Laboratories) - Period of Performance: One year (Sept 30, 2026 – Sept 29, 2027) - Unique Requirement: Continuity with Metabolon's proprietary platform; no alternative vendors specified - Commercial Opportunity: Sole source, but similar labs with advanced metabolomics capabilities may be interested in future opportunities

Description

Metabolomic Analysis of the Effects of Phenylbutyrate (PB) in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

View original listing